AgomAb (AGMB) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Initiated Coverage | Overweight | $60.00 | Aug 25, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Aug 19, 2026 |
| B. Riley Securities | Initiated Coverage | Buy | $34.00 | Jul 23, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $35.00 | Jun 22, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $28.00 | Mar 3, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $36.00 | Mar 3, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $32.00 | Mar 3, 2026 |
Frequently asked questions
What is the price target for AGMB stock?
The average 12-month analyst price target for AgomAb (AGMB) is $43.00, with a high estimate of $60.00 and a low of $34.00, across 3 analysts.
Is AGMB a buy, sell, or hold?
Analysts covering AgomAb currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for AGMB?
The average price target of $43.00 implies 229.00% upside from the last price of $13.07.
What is the latest analyst rating on AGMB?
On Aug 25, 2026, Piper Sandler initiated coverage of AgomAb at Overweight with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.